electroCore (NASDAQ: ECOR) is one of 47 public companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare electroCore to related companies based on the strength of its risk, dividends, valuation, earnings, analyst recommendations, profitability and institutional ownership.
Insider and Institutional Ownership
14.5% of electroCore shares are held by institutional investors. Comparatively, 48.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares electroCore and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|electroCore Competitors||$1.19 billion||$88.54 million||17.38|
electroCore’s peers have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares electroCore and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for electroCore and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
electroCore presently has a consensus target price of $21.50, indicating a potential upside of 252.46%. As a group, “Electromedical equipment” companies have a potential upside of 28.13%. Given electroCore’s stronger consensus rating and higher possible upside, equities research analysts clearly believe electroCore is more favorable than its peers.
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.